WEKO3
アイテム
{"_buckets": {"deposit": "49c03d91-15a4-4d71-b033-7bcf66e0dcdf"}, "_deposit": {"created_by": 2, "id": "1072", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "1072"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00001072", "sets": ["9"]}, "author_link": ["5139", "5144", "5142", "5137", "5143", "5141", "5145", "5146", "5140", "5138"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-01", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "184", "bibliographicPageStart": "178", "bibliographicVolumeNumber": "135", "bibliographic_titles": [{"bibliographic_title": "Diabetes Research and Clinical Practice"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Aims Sodium-glucose cotransporter 2 inhibitors (SGLT2i) cause substantially less weight loss than would be expected based on their caloric deficits, probably due to enhanced appetite regulation known as “compensatory hyperphagia,” which occurs to offset the negative energy balance caused by increased glycosuria. We examined whether any specific nutrients contributed to the compensatory hyperphagia in diabetic patients taking SGLT2i. Methods Sixteen patients with type 2 diabetes were newly administered dapagliflozin 5 mg daily as the experimental SGLT2i group. Sixteen age-, sex- and BMI-matched type 2 diabetes patients not receiving dapagliflozin served as controls. A brief-type self-administered diet history questionnaire (BDHQ) was undertaken just before and 3 months after study initiation to evaluate changes of energy and nutrient intakes in each group. Results At 3 months, daily intakes of total calories and the proportions of the three major nutrients were not significantly increased in either group. However, daily sucrose intake was significantly increased after treatment versus the baseline value in the SGLT2i group (p =.003), but not in controls. The calculated intakes of all other nutrients were not significantly changed in either group. Conclusions Dapagliflozin treatment specifically increased sucrose intake, which might be an ideal target for nutritional approaches to attenuate compensatory hyperphagia.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Diabetes Research and Clinical Practice, 135, pp.178-184; 2018", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier B.V."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.diabres.2017.11.016", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2017 Elsevier B.V."}, {"subitem_rights": "This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "01688227", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Horie, Ichiro"}], "nameIdentifiers": [{"nameIdentifier": "5137", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Abiru, Norio"}], "nameIdentifiers": [{"nameIdentifier": "5138", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hongo, Ryoko"}], "nameIdentifiers": [{"nameIdentifier": "5139", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "5140", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Ayako"}], "nameIdentifiers": [{"nameIdentifier": "5141", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Haraguchi, Ai"}], "nameIdentifiers": [{"nameIdentifier": "5142", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Natsuda, Shoko"}], "nameIdentifiers": [{"nameIdentifier": "5143", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sagara, Ikuko"}], "nameIdentifiers": [{"nameIdentifier": "5144", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ando, Takao"}], "nameIdentifiers": [{"nameIdentifier": "5145", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawakami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "5146", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "DRCP135_178.pdf", "filesize": [{"value": "608.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 608200.0, "url": {"label": "DRCP135_178.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/1072/files/DRCP135_178.pdf"}, "version_id": "822a2f52-81cf-46bf-9482-94c6412b5ac0"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "BDHQ", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Dapagliflozin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Diet history", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Hyperphagia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "SGLT2", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Sugar", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/38317", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-02-01"}, "publish_date": "2019-02-01", "publish_status": "0", "recid": "1072", "relation": {}, "relation_version_is_last": true, "title": ["Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment"], "weko_shared_id": -1}
Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment
http://hdl.handle.net/10069/38317
http://hdl.handle.net/10069/383174ecd267f-7e3a-43a4-aedb-1e3ee6d26f3c
名前 / ファイル | ライセンス | アクション |
---|---|---|
DRCP135_178.pdf (608.2 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-02-01 | |||||
タイトル | ||||||
タイトル | Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | BDHQ | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Dapagliflozin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Diet history | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Hyperphagia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | SGLT2 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Sugar | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Horie, Ichiro
× Horie, Ichiro× Abiru, Norio× Hongo, Ryoko× Nakamura, Takeshi× Ito, Ayako× Haraguchi, Ai× Natsuda, Shoko× Sagara, Ikuko× Ando, Takao× Kawakami, Atsushi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Aims Sodium-glucose cotransporter 2 inhibitors (SGLT2i) cause substantially less weight loss than would be expected based on their caloric deficits, probably due to enhanced appetite regulation known as “compensatory hyperphagia,” which occurs to offset the negative energy balance caused by increased glycosuria. We examined whether any specific nutrients contributed to the compensatory hyperphagia in diabetic patients taking SGLT2i. Methods Sixteen patients with type 2 diabetes were newly administered dapagliflozin 5 mg daily as the experimental SGLT2i group. Sixteen age-, sex- and BMI-matched type 2 diabetes patients not receiving dapagliflozin served as controls. A brief-type self-administered diet history questionnaire (BDHQ) was undertaken just before and 3 months after study initiation to evaluate changes of energy and nutrient intakes in each group. Results At 3 months, daily intakes of total calories and the proportions of the three major nutrients were not significantly increased in either group. However, daily sucrose intake was significantly increased after treatment versus the baseline value in the SGLT2i group (p =.003), but not in controls. The calculated intakes of all other nutrients were not significantly changed in either group. Conclusions Dapagliflozin treatment specifically increased sucrose intake, which might be an ideal target for nutritional approaches to attenuate compensatory hyperphagia. | |||||
書誌情報 |
Diabetes Research and Clinical Practice 巻 135, p. 178-184, 発行日 2018-01 |
|||||
出版者 | ||||||
出版者 | Elsevier B.V. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 01688227 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.diabres.2017.11.016 | |||||
権利 | ||||||
権利情報 | c 2017 Elsevier B.V. | |||||
権利 | ||||||
権利情報 | This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Diabetes Research and Clinical Practice, 135, pp.178-184; 2018 |